According to filings with the U.S. Securities and Exchange Commission, Olema Pharmaceuticals is raising $130,000,000.00 in new funding. Sources indicate that as part of senior management Chief Executive Officer, Cyrus Harman played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Olema Pharmaceuticals
Olema Oncology is a biopharmaceutical company developing innovative targeted therapies for womens cancers. Our lead program, OP-1250, a potential best-in-class complete estrogen receptor antagonist (CERAN), is in development to treat estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer. Olema recently initiated a Phase 1/2 dose-escalation and expansion clinical trial of OP-1250. We are supported in our mission by experienced and accomplished scientists and board members, leading healthcare investors and some of the most innovative pharma companies. For more information about the company please visit www.olema.com. Note: Olema will not conduct interviews via text message or messaging platforms and will not ask you to download anything as part of your interview. Though we use third party tools to help with advertising our jobs, please be vigilant in checking that the communication is in fact coming from Olema.

To learn more about Olema Pharmaceuticals, visit http://www.olemapharma.com/

Contact:
Cyrus Harman, Chief Executive Officer
415-651-3316
https://www.linkedin.com/in/cyrus-harmon-6024193/

SOURCE: http://www.intelligence360.io
Copyright (c) 2023 SI360 Inc. All rights reserved.